We are Healthy
U.S.

Drug Could Ease GLP-1 Vomiting, Phase 3 Trial Finds

Adults on GLP-1 medications saw fewer vomiting episodes on tradipitant than on placebo in a phase 3 study.

Updated on Nov. 4, 2026 in Diabetes

Isometric editorial illustration of a plain white tablet beside an empty amber dropper bottle on a pale surface, evoking a medication for side effects.
Vanda Pharmaceuticals reported positive phase 3 results showing its drug tradipitant reduced vomiting in adults taking GLP-1 medications such as semaglutide. AI Illustration. Upload story photo >

Live Poll

Would you trust a new medication to ease nausea from weight-loss drugs?

Vanda Pharmaceuticals reported positive topline results from a phase 3 trial testing its drug tradipitant for preventing vomiting caused by GLP-1 medications such as semaglutide. The company plans to seek an expanded approval for this use, which could matter for adults taking these drugs for obesity or diabetes.

Why it matters

GLP-1 drugs are widely used for weight management and diabetes, and nausea and vomiting are among their most common side effects that lead people to stop treatment. A reduction in these symptoms could make the medications more tolerable for some users, and the company says the trial results are the basis for its planned regulatory filing.

This randomized, double-blind, placebo-controlled phase 3 trial enrolled 306 adults with obesity or overweight and at least one weight-related condition, with 142 assigned to tradipitant and 164 to placebo. The primary comparison showed a 27% relative reduction in overall vomiting, while the headline secondary results and exploratory analyses point to reductions in more severe vomiting episodes.

The players

Vanda Pharmaceuticals

A U.S. biopharmaceutical company that develops treatments for sleep, mood, and gastrointestinal conditions, and the sponsor of tradipitant.

The details

Participants took a single 1 mg challenge dose of semaglutide before being randomized to tradipitant or placebo taken orally twice daily for about two weeks. Vomiting was tracked over 24-hour periods using a standardized daily diary. The company reported that tradipitant was generally well tolerated and that no new safety signals emerged in the study.

Timeline

  1. October 27, 2026: Vanda announced the Study 3601 positive results in a news release.

  2. November 4, 2026: Renal and Urology News published coverage of the results.

Health Landscape

GLP-1 receptor agonists such as semaglutide have become central to obesity and type 2 diabetes care, and nausea is among the most common reasons people discontinue them. This trial adds to efforts to manage those side effects so that patients can stay on therapy.

If you take a GLP-1 medication and have struggled with nausea or vomiting, this research may eventually offer a new option to discuss with your doctor. Any change in care would depend on regulatory approval, so current treatment decisions should be made with your prescriber.

The takeaway

Nausea is a common reason people stop GLP-1 treatment, so research into managing it matters for long-term use. If side effects are affecting you, raise them with your doctor, who can review options that fit your situation.

What happens next

Vanda Pharmaceuticals plans to submit a supplemental New Drug Application seeking an expanded indication for GLP-1-induced vomiting, though no submission date was given.

Further reading

For broader context on how these medications are used, explore Diabetes coverage.

More information

Read the Vanda Pharmaceuticals Study 3601 results news release for the company's full account of the trial.

Live Poll

Would you trust a new medication to ease nausea from weight-loss drugs?